Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-viral analogues - Protheragen

Next Previous
Drug Profile

Research programme: anti-viral analogues - Protheragen

Alternative Names: TRPML3 inhibitors

Latest Information Update: 11 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protheragen
  • Class Antivirals; Small molecules
  • Mechanism of Action Transient receptor potential channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Coronavirus infections; Viral infections

Highest Development Phases

  • Preclinical Coronavirus infections; Viral infections

Most Recent Events

  • 11 Oct 2021 Research programme: anti-viral analogues - Protheragen is available for licensing as of 11 Oct 2021. https://www.protheragen.com/available-projects/antiviral-small-molecule-extracted-from-plants/
  • 11 Oct 2021 Protheragen has patent protection for berbamine and its derivative compounds before October 2021 (Protheragen's pipeline, October 2021)
  • 11 Oct 2021 Protheragen announced IND approval for berbamine analogues in viral infections before October 2021 (Protheragen's pipeline, October 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top